Top Story Today
Vertex Bets $10 Billion It Can Outgrow Cystic Fibrosis
Vertex is paying $10 billion (a 102% premium) to acquire Crinetics Pharmaceuticals, a rare endocrine disease company with an approved oral acromegaly drug and a strong late-stage pipeline. It's the largest deal in Vertex history, and it won't pay for itself until 2029. The move adds a fifth growth pillar alongside pain, hematology, renal, and CF, funded by the massive cash flows from its dominant cystic fibrosis franchise. Vertex shares dipped on the news, but the long-term message is unmistakable: the CF company wants to stop being called the CF company.
Why it matters: This deal accelerates Vertex's transformation from a single-disease powerhouse into a diversified specialty pharma, and the escalating size of its acquisitions ($950M in 2019, $4.9B in 2024, $10B now) signals that the company sees diversification as existential, not optional.
Read more →Clinical and Regulatory
The Antibody That Just Ended Trastuzumab's 20-Year Reign in Stomach Cancer
Jazz Pharmaceuticals' Ziihera became the first bispecific antibody approved for first-line HER2-positive gastric cancer, posting median overall survival of 26.4 months (the longest ever seen in a Phase 3 gastric trial). The drug beat trastuzumab head-to-head, cutting the risk of death by 28%. After two decades of one-size-fits-all HER2 therapy, stomach cancer patients finally have a genuinely better first option.
Read more →A Blood Disorder Gets Its First FDA-Approved Drug After Decades of Nothing
J&J's Imaavy became the first drug ever approved for warm autoimmune hemolytic anemia, a condition affecting roughly 40,000 Americans whose immune systems destroy their own red blood cells. The approximately 72% durable response rate in the 30 mg/kg group — about three times the placebo rate — won't cure everyone, but for a disease that relied entirely on off-label steroids, it's a genuine milestone. A wave of competitors, including Sanofi's rilzabrutinib, is already lined up behind it.
Read more →Ivonescimab Topples Durvalumab in Bile Duct Cancer, a First for Any Drug
Akeso's bispecific antibody ivonescimab beat durvalumab head-to-head in first-line biliary tract cancer, hitting overall survival at an interim analysis. It's the first Phase 3 trial ever to show a survival win over a PD-L1 inhibitor combo in this disease. Full numbers haven't dropped yet, but the cross-tumor pattern (lung cancer, bile duct cancer) is building a case that's getting harder to dismiss.
Read more →TL1A Stumbles in Rheumatoid Arthritis, Raising Questions for the Entire Field
Spyre's TL1A antibody showed statistically significant activity in a Phase 2 RA trial but the effect size did not meet the company's internal threshold for continued RA monotherapy development. The company called it "proof of mechanism" and deprioritized RA monotherapy while framing the findings as supportive of use in other autoimmune diseases and combination settings. With Merck, Roche, and Sanofi collectively committing approximately $18.5 billion in upfront and acquisition value on TL1A bets, the result raises pointed questions about whether the hottest target in biotech works outside the gut.
Read more →Deals and M&A
McKesson Buys a CRO for $2.25 Billion, Blurring the Line Between Shipping and Science
The pharma distribution giant is acquiring Precision Medicine Group, a biomarker-driven contract research organization managing 600+ clinical trials and 30 million biospecimens. It's the latest step in McKesson's deliberate migration from pill logistics into specialty care and clinical development. Expect the other big distributors (Cencora, Cardinal Health) to respond in kind.
Read more →AstraZeneca Drops $1.77 Billion on Kidney-Targeted RNA Drugs That Don't Exist Yet
AstraZeneca partnered with China's CSPC to co-discover two siRNA candidates for kidney disease, paying $30 million upfront with up to $1.77 billion in milestones. The programs are preclinical with no named targets, but the real prize is CSPC's extrahepatic delivery technology. If RNA drugs can finally escape the liver and reach the kidneys, this deal looks like a bargain.
Read more →Ipsen Closes $1.75 Billion Bet on a Myelofibrosis Drug That Ignores JAK Entirely
The French pharma completed its acquisition of Kartos Therapeutics, paying $450 million upfront (plus $1.3 billion in milestones) for navtemadlin, an MDM2 inhibitor that reactivates cancer cells' self-destruct button. Phase 3 data showed a numerically higher spleen reduction rate than standard therapy, though the difference did not reach statistical significance. It's Ipsen's boldest move yet in a deliberate pivot toward hematology.
Read more →Devices and Legal
Abbott's New Wearable Tracks Glucose and Ketones Simultaneously, a World First
The FDA authorized Abbott's Libre Duo 10 Day, the first sensor that continuously monitors both glucose and ketones at once. For patients on SGLT2 inhibitors or insulin pumps, ketone spikes can trigger life-threatening diabetic ketoacidosis, sometimes without any glucose warning. The device was cleared through the De Novo pathway (reserved for truly novel tech) for ages 2 and up.
Read more →RA Capital Found Liable for Stealing Yale's Trade Secrets to Build a Competitor
A federal court ruled that RA Capital, one of biotech's most prominent investors, willfully misappropriated a targeted protein degradation trade secret from Yale after confidential deal negotiations fell apart. The $4 million judgment is pocket change for a firm managing over $14 billion in assets, but the reputational damage and precedent for how investors handle academic IP could echo across the industry for years.
Read more →